BR112023025459A2 - Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos - Google Patents

Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos

Info

Publication number
BR112023025459A2
BR112023025459A2 BR112023025459A BR112023025459A BR112023025459A2 BR 112023025459 A2 BR112023025459 A2 BR 112023025459A2 BR 112023025459 A BR112023025459 A BR 112023025459A BR 112023025459 A BR112023025459 A BR 112023025459A BR 112023025459 A2 BR112023025459 A2 BR 112023025459A2
Authority
BR
Brazil
Prior art keywords
methods
tyrosine kinase
kinase inhibitors
bruton
malignancies
Prior art date
Application number
BR112023025459A
Other languages
English (en)
Inventor
Ivo Cornelissen
Alexander Palmer James
D Venable Jennifer
H Leu Jocelyn
J M Wiener John
E Packman Kathryn
S Tichenor Mark
Navin Rao
Sriram Balasubramanian
Ulrike Philippar
Xin Miao
Yue Guo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023025459A2 publication Critical patent/BR112023025459A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

nibidores da tirosina quinase de bruton e métodos de uso dos mesmos. a presente invenção refere-se ao uso de um composto da fórmula (iii) no tratamento de malignidades.
BR112023025459A 2021-06-04 2022-06-02 Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos BR112023025459A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (1)

Publication Number Publication Date
BR112023025459A2 true BR112023025459A2 (pt) 2024-02-27

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025459A BR112023025459A2 (pt) 2021-06-04 2022-06-02 Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos

Country Status (13)

Country Link
US (1) US20230013755A1 (pt)
EP (1) EP4346834A1 (pt)
JP (1) JP2024520630A (pt)
KR (1) KR20240019214A (pt)
CN (1) CN117412753A (pt)
AU (1) AU2022284369A1 (pt)
BR (1) BR112023025459A2 (pt)
CA (1) CA3220015A1 (pt)
CL (1) CL2023003564A1 (pt)
IL (1) IL308951A (pt)
MX (1) MX2023014435A (pt)
TW (1) TW202317127A (pt)
WO (1) WO2022254371A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887697A1 (en) 2012-10-11 2014-04-17 Pharmacyclics, Inc. Companion diagnostics for tec family kinase inhibitor therapy
DK3179991T3 (da) * 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
TW202317127A (zh) 2023-05-01
AU2022284369A1 (en) 2024-01-25
CL2023003564A1 (es) 2024-06-21
IL308951A (en) 2024-01-01
WO2022254371A1 (en) 2022-12-08
US20230013755A1 (en) 2023-01-19
KR20240019214A (ko) 2024-02-14
EP4346834A1 (en) 2024-04-10
MX2023014435A (es) 2024-03-08
CN117412753A (zh) 2024-01-16
JP2024520630A (ja) 2024-05-24
CA3220015A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
BR112022019611A2 (pt) Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso
BR112022014058A2 (pt) Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DK1272188T3 (da) Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
UY28441A1 (es) Derivados de quinazolina
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DE60220771D1 (de) Hemmer von cyclinabhängigen kinasen als mittel gegen krebs
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BRPI0513857A (pt) inibidores de hsp90
BR112023025459A2 (pt) Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
CL2022002699A1 (es) Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.
WO2024044744A3 (en) Peroxiredoxin 3 inhibitors and methods of use for treating cancer